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ToxicityAbstract Background: Concerns over inappropriate use of cough and cold medication (CCM) in
children have been raised. In addition to being ineffective, these are now considered toxic for young
children. Despite this fact studies from some regions have shown high use of these medications by
physicians. However data on pediatricians and from India are negligible. Aim: To study the burden
and patterns of cough and cold medications use by pediatricians for hypothetical cases.Methods: In
this cross-sectional study; 172 pediatricians of various hospitals of Delhi and Haryana were enrolled
from February 15 to March 15, 2012. They were contacted personally by authors and asked to write
their prescriptions for two hypothetical case scenarios [having cough and cold] of two different age
groups; (1) less than 2 years and (2) 2–5 years. We made two categories as recommendations exist
for children less than 2 years while recommendations for the second category are underway. Results
were summarized as percentages, counts and; presented in tables and ﬁgures. Chi square test was
used to establish association between categorical variables of subgroups. Results: Response rate
was 93%. The most used CCM was antihistaminics (82%) and systemic sympathomimetics
(48%). The use of CCM was signiﬁcantly less in teaching hospitals as compared to non-teaching
Pediatrician’s prescription of cough and cold medication for hypothetical cases 177(77% vs. 95%; p-value – 0.025). However there was no statistical difference in the practice of post
graduates and more senior pediatricians (p value-0.895). No difference in CCM use in two age
groups {(82% (less than 2 years) vs. 85% (2–5 years); p-value – 0.531} was observed. Conclusion:
Overall use of CCM is still high irrespective of patient age, pediatrician’s seniority or hospital
setting. Efforts should be made to create awareness among the pediatricians regarding cautious
use of these medications.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cough and cold is the most common cause for hospital visits,
and so is the use of cough and cold medication (CCM). A
cough and cold medication has been considered to contain a
single ingredient (SI) or multiple ingredients (MI) like promet-
hazine (PRZ), chlorpheniramine (CPM), pseudoephedrine
(PS), phenylephrine (PE), diphenhydramine (DPH), dex-
tromethorphan (DXT), guanfeneisin and ambroxol. These
ingredients have many deleterious side effects like respiratory
depression, apnea, seizures, stroke and cerebral hemorrhage
as well as cardiac adverse effects like hypertension dysrhyth-
mias and even death. Overuse and potential health hazards
of CCM are well recognized. The Centers for Disease
Control reported deaths associated with use of pseu-
doephedrine and dextromethorphan (CDC, 2007).
Additionally ten infant deaths associated with use of OTC
CCMs were identiﬁed in a one year period through review of
ACFRP data (Rimsza and Newberry, 2008). These infants
were exposed to pseudoephedrine (3 patients {pt.}), chlor-
pheniramine (2pt.), dextromethorphan (2pt.), promethazine
(1pt.) and ambroxol (2pt.).Similarly Marinetti et al. associated
the death of 10 infants with ingestion of OTC CCM (Marinetti
et al., 2005). Furthermore Wingert et al. linked the death of 13
infants and 2 toddlers with administration of OTC CCM
(Wingert et al., 2007). The adverse events are linked to erro-
neous overdosing and self-medication by parents/caregivers
but the exact prescription burden in our country, by pediatri-
cians is not known. Hence this study was done to evaluate and
document the current burden of CCM use by pediatricians
so that interventions can be formulated to reduce such
preventable deaths.
2. Methods
2.1. Study design and setting
This cross-sectional, hypothetical case based study was
conducted among pediatricians from February 15 to March
15, 2012. It covered three teaching tertiary care hospitals and
two non-teaching hospitals (all government) of Delhi and
Haryana. These hospitals have postgraduates (PG) from all
over India and senior residents from nearby states like Uttar
Pradesh, Bihar, Punjab, Rajasthan, Odisha and West Bengal.
Some of them go back to their home towns for practice/
work after completing PG and some after completing their
residency. Similarly many pediatricians, after their post-
graduation in their home town come to Delhi and Haryana
for doing residency. In a way their practice should be the
representation of north India.2.2. Sample size and sampling technique
Sample size was calculated using single proportion formula
(n= [Za/2]2 p (1  p]/d2) at 95% conﬁdence interval, where,
Za/2 = 1.96, p= prevalence of 35% was taken from a pre-
vious study from Gujarat (Patel et al., 2013), and d= 5% of
marginal error was taken. Using this calculation we obtained
349 to be the sample size. Since the exact number of respon-
dent population is less than 10,000; we used correction formula
of nf= ni/(1 + ni/N) where nf = corrected sample size,
ni= uncorrected sample size, and N= total respondents
(Thrusﬁeld, 1995). Hence, (349/1 + 349/250 = 146), we
obtained a sample size of 146. Additional 15% was added
for not responding pediatricians, making a ﬁnal sample size
of 167. The participants were selected using convenience sam-
pling technique. The total sample size was distributed propor-
tionately among the various hospitals. The pediatricians who
refused to participate and those with illegible hand writing
were excluded from the study.
2.3. Study instrument
The predesigned, self-administered proforma contained two
case scenarios of two different age groups; (1) less than 2 years
and (2) 2–5 years written separately on proforma. The case sce-
nario was ‘‘a child with cough and cold for last two days that is
stable and his chest examination is normal’’ (Annexure 1). The
pediatricians were asked to write prescriptions for these two
case scenarios. The purpose was to see the difference in pattern
of use of CCM as recommendations differ in two age groups.
A pretest of proforma was carried out on 10 pediatricians for
acceptability and feasibility, who were not included in the
study.
2.4. Data collection
Authors (SC, MD and MS) collected the data by contacting
172 pediatricians personally in outpatient and inpatient
departments during working hours. Three consecutive days
were allotted for a single hospital during the study period.
After explaining the purpose of the survey, pediatricians were
given the proforma. The proformas were taken back soon after
the participants ﬁlled it and sealed. These were later opened
together for analysis.
2.5. Ethical clearance
The study was approved by institutional review board. Verbal
consent of participants was obtained. Conﬁdentiality of the
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various constituents
Frequency of constituents used
in various CCM products
< 2 yrs (Total
prescription-
121/148)
 2-5 yrs (Total
prescription-
126/148)
Figure 2 Frequency of constituents used in various CCM
products (results are overlapping).
178 S. Chandelia et al.participants was maintained and their right to withdraw from
the survey any time was assured.
2.6. Statistical analysis
Descriptive statistics was used to illustrate responses of the
participants. Categorical variables were measured as counts
and percentages. Statistical analysis was done using SPSS
software. Chi square test was used for calculation of p value
(signiﬁcant at <0.05) as the data were categorical. IDR i triple
was used to decode the constituents of the CCM products
written by pediatricians.
3. Results
Of the 172 pediatricians contacted, 159 (93%) consented to
participate. 11 Proformae were excluded due to illegible hand
writing making a total 148 for ﬁnal analysis. Of these, post-
graduate students were 30 and rests were seniors (senior resi-
dents and assistant professors) as shown in Fig. 1. CCM
were used by 82% and 85% pediatricians for less than 2 yrs
and 2–5 yrs of age groups respectively and there was sta-
tistically signiﬁcant difference in CCM prescription according
to age. 68% pediatricians wrote different CCM for different
age categories while 32% used same product for both age
groups but differing in dose. Majority of pediatricians used a
MI product with a combination of at least two ingredients
(48%); three ingredients (27%) and rest used a SI product.
Use of MI CCM consisting of PE and CPM was universal in
both age groups and all centers except one where 51% pedia-
tricians used a combination of PS and CPM. The use of CTZ
was more in babies older than 2 yrs while PRZ and mucolytics
were more used in younger babies. Fig. 2 shows the frequency
of use of different constituents. The frequency of the most
commonly used product (combination of PE + CPM) was
QID, TDS, BD and OD in 27%, 68%, 3% and 2% prescrip-
tions respectively. This was similar for PRZ, DPH and CTZ.Total pediatricians contacted (172) 
Refused to participate (13) 
Consented to participate (159) 
Excluded due to illegible 
hand -writing (11) 
Final total participants for analysis n = (148) 
Teaching hospitals (111) Non-Teaching hospitals (37) 
centre1   
(51) 
Centre 2 
(32) 
Centre 4 
(25) 
Centre 3 
(28) 
Centre 5 
(12) 
Figure 1 Flow diagram showing distribution of participants in
various centers.The duration of treatment was 3 days, 5 days and 7 days in
47%, 42% and 11% prescriptions respectively. 33% pediatri-
cians wrote same duration for either age group. Seven percent
participants combine two different products containing SI and
MI e.g. [(PE/PS + CPM) + DXT] or [(PE/PS + CPM) +
ambroxol] or [PE/PS + CPM) + DXT+ ambroxol]. All
pediatricians wrote brand name of preparations. Only two par-
ticipants wrote constituents in bracket. None of the pediatri-
cian wrote the concentration of the ingredients. For babies
younger than 2 yrs.; 22% pediatricians write medications in
drops, 36% pediatricians in (tea spoon full) tsf and 42% pedia-
tricians in ml. Table 1 shows the difference in CCM use among
different centers. Center 1 has signiﬁcantly less CCM usage as
compared to others (59%, p value 0.001). A signiﬁcantly less
CCM usage was also observed in teaching hospitals as com-
pared to non-teaching (p value 0.025). However no difference
in CCM use between PG and seniors was found (Table 1).
The results, for which patient age is not mentioned dis-
tinctly, are for the 2–5 yrs age group.
4. Discussion
CCM use is still high even after two decades of recognition of
their doubtful efﬁcacy and documented toxicity. A recentTable 1 Difference in CCM use by different categories of
pediatricians and patients.
CCM use in Number of
participants
p-
value
Teaching center 1 vs Teaching
center (2 + 3)
30/51 vs 56/60 0.001
Teaching vs non-teaching hospitals 86/111 vs 35/37 0.025
PG vs Seniors (All Teaching centers) 24/30 vs 62/81 0.895
Patient age <2 yrs vs 2–5 yrs (all
centers)
121/148 vs 126/148 0.531
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remains high despite the national warnings against their use
(Sen et al., 2011). There is no difference in CCM use according
to patient age. Mostly Pediatricians, who refrain from CCM,
do not use it for either age group. However differences
in choice of CCM in different age group were noticed, the
basis of which, is difﬁcult to explain as there are no
guidelines suggesting which CCM is to be preferred in a
particular age.
MI CCM is prescribed by 75% pediatricians and 7% pedia-
tricians wrote more than one product for a single patient, may
be keeping in view the different mechanism of action of con-
stituent drugs for getting maximum possible beneﬁt. But this
situation is more dangerous since these constituents alone
can cause life threatening events and using 2–3 ingredients
would increase the chances of augmentation of toxic effects.
Additionally, multiple ingredients in a formulation increase
the risk of drug interactions and surely the cost.
Among the systemic decongestants, PE was used by 76%
and 20% used PS. Earlier in the Slone survey in U.S., the expo-
sure to PS was highest but now it has decreased because of the
2005 Combat Methamphetamine Epidemic Act, due to which
pharmaceutical companies started to replace it by PE
(Vernacchio et al., 2008). Potential health hazards and overuse
of PS are known, but now in the coming years it will be impor-
tant to monitor for the toxicities of PE in children.
The use of mucolytics was more in babies younger than
2 yrs. It may be because of the general fact that they are not
able to cough out the secretions. Although we had not cat-
egorized the case scenarios as having dry/wet cough.
We observed different frequencies for same medication
which is not rational. The use of CCM seemed to be hospital
speciﬁc. Particular types of brands of CCM were used in a par-
ticular hospital. This may be because of inﬂuence of promotion
by medical representatives. Many pediatricians write CCM in
tsf which is more prone to dosing errors. Studies show that
variations in liquid CCM dosing with spoons can be up to
20%, which can increase the risk of overdosing and adverse
events (Wansink and van Ittersum, 2010).
Our results show that CCM use differs among centers sig-
niﬁcantly depicting more rational approach of one teaching
center which resulted in more appropriate practice of teaching
hospitals over Nonteaching hospitals (without which there had
been no difference between the both settings of hospitals). We
can assume them to be more updated than others and those
might have adapted to the U.S FDA advice regarding
restricted use of CCM (FDA Public Health Advisory, 2013).
However there was no difference in practice of PG and seniors.
It is usually thought that with more years of professional
experience a doctor tends to be a more rational prescriber,
but in this study we did not ﬁnd such association which implies
that PGs follow their senior’s practice and if seniors could
restrict from using CCM by spending more time in counseling
the patient, the exposure to CCM would have been very less.
Pediatricians should encourage the parents to use non-
pharmacological measures for symptomatic relief of cough
and cold.
A wide prescription variation shows the lack of uniform
guidelines on the topic. The overuse is despite the absence ofany overt policy on their use (Sharfstein et al., 2007). This is
very surprising and unfortunate that these medications are
considered social and harmless even in the absence of enough
evidence of their safety as well as efﬁcacy (Smith et al., 2008;
Vassilev et al., 2010). Especially in the absence of efﬁcacy their
toxicities should not be accepted. The US and UK has intro-
duced a warning regarding cautious use of these medications
in their countries but no such caution has been seen in India.
Doyon et al. and Shehab et al. show that CCM-related adverse
events among children were substantially reduced after with-
drawal of over-the-counter CCM (Doyon et al., 2012;
Shehab et al., 2010). This should be taken as enough evidence
for promoting nonuse of CCM.
In U.S. the researchers found the use of cough and cold
medications declined from 12.3% in 1999–2000 to 8.4% in
2005–2006 (Vernacchio et al., 2008). On the other hand
Fatma et al. showed that a warning did not result in decreased
prescriptions of CCM (Sen et al., 2011). The pediatricians
should make efforts to reduce the CCM use on individual basis.
The strength of the study is a calculated sample size,
higher response rate and larger coverage of participants of
ﬁve hospitals showing generalizability of results. Other stud-
ies which conduct surveys through mails or electronic mail
have shown response rates of less than 60% which is not
considered to be optimum. Higher response rate seen in
our study is due to the personal contact to the participants
by the authors themselves. Study is good for assessing the
current knowledge of pediatricians. In the actual out-patient
setting pediatricians may not get time to counsel the patients
due to work load. They may be forced to write some med-
ication under parental pressure despite knowing the ineffec-
tiveness of these medications. It is expected that for
hypothetical case they will not face such problems and will
write evidence based correct prescription. The study has
few limitations. The clinicians may not come out with actual
practice and CCM use may be much higher. Actual prescrip-
tion analysis could have been closer to real CCM burden.
This study (given the design of the study) has shown most
pediatricians are not aware of the toxicities or doubtful effec-
tiveness of CCM due to which the use is high. In a similar
observation by Chandelia et al., where actual prescriptions
were examined in a single institution, the results were similar
(Chandelia and Khanna, 2013). Although we use CCM in
the beneﬁt of the patient but we have to recognize that the
fatalities associated with CCM cannot be overlooked.
5. Conclusions
Although one center shows signiﬁcantly less usage, high
CCM use persists irrespective of age of patient, seniority of
clinician or hospital setting. There is a need to realize and
edify our prescriptions regarding the restricted use of these
medications. In future studies the causes of higher CCM
use should be hit upon.
Appendix A
See Annexure 1.
Annexure 1 (clinical case scenario)
Designation:
Hospital:                     
1. A child less than 2 years comes to you in OPD with complaints of cough and cold for last 
two days. He is feeding well. His vitals are stable and chest examination is normal. Write 
your prescription for this child. 
2. A child in age group 2-5 years comes to you with similar presentation as mentioned 
above. Write your prescription for such a child .
Annexure 1
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